Our in vivo study showed that T2A inhibited angiogenesis and tumor growth through the inhibition of HIF-1α expression, confirming that HIF-1α inhibition was involved in the antiangiogenic activity of T2A. The gene discussed is HIF1A; the disease is neoplasm.